铜对于瘤性BRAF信号传递和瘤发生是必需的
Donita C Brady1, Matthew S Crowe1, Michelle L Turski1
1Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Nature
|April 11, 2014
概括
铜化疗法可以治疗BRAF (V600E) 癌症. 减少铜载体1 (CTR1) 或破坏铜与MEK1的结合,可以抑制BRAF (V600E) 信号和瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- BRAF激酶突变,特别是V600E,是黑色素瘤和其他癌症的致癌驱动因素.
- BRAF-MEK-ERK信号通路 (MAPK通路) 对癌细胞增殖至关重要.
- 之前已经证明,铜 (Cu) 流入增强了MEK1-ERK1/2酸化.
研究的目的:
- 调查铜在BRAF (V600E) 驱动的癌症信号传递和瘤发生中的作用.
- 探索针对铜运输或结合在BRAF (V600E) 癌症中的治疗潜力.
主要方法:
- 评估了CTR1水平和MEK1突变对小鼠和人类细胞模型中的BRAF (V600E) 信号传导的影响.
- 使用MEK1-MEK5仿真机和活跃的ERK2来评估不依赖铜的信号.
- 在BRAF (V600E) 转换细胞和耐药模型中测试了铜合剂的疗效.
主要成果:
- 降低CTR1或破坏Cu-MEK1相互作用降低了BRAF (V600E) 信号和瘤生长.
- 铜独立信号恢复在Ctr1缺陷细胞中挽救了瘤生长.
- 铜合剂抑制了BRAF ((V600E) 和BRAF抑制剂耐药癌症的瘤生长.
结论:
- 铜流入和MEK1铜结合对BRAF (V600E) 驱动的瘤发生至关重要.
- 铜化疗法显示出作为BRAF (V600E) 突变癌症的重定向治疗的前景.
- 向铜代谢为BRAF突变癌症提供了一种新的治疗策略,包括对BRAF抑制剂耐药的癌症.
相关概念视频
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression
1.5K
1.5K
The Ras Gene
5.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
5.7K
Cancer-Critical Genes I: Proto-oncogenes
9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
Cancer-Critical Genes I: Proto-oncogenes
6.1K
6.1K
MAPK Signaling Cascades
7.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K


